Assunta Santonati1, Andrea Palermo1, Ernesto Maddaloni1, Daniela Bosco1, Antonio Spada1, Franco Grimaldi1, Bruno Raggiunti1, Raffaele Volpe1, Silvia Manfrini1, Fabio Vescini1. 1. Department of Endocrinology (A.Sa., D.B., A.Sp.), San Giovanni Addolorata Hospital, 00184 Rome, Italy; Department of Endocrinology and Diabetes (A.P., E.M., S.M.), University Campus Bio-Medico, 00128 Rome, Italy; Department of Endocrinology and Diabetes (F.G., F.V.), Santa Maria della Misericordia Hospital, 33100 Udine, Italy; Department of Endocrinology (B.R.), Hospital San Liberatore Atri, 64032 Teramo Italy; and Department of Endocrinology (R.V.), Cardarelli Hospital, 80131 Naples, Italy.
Abstract
CONTEXT: Conventional therapy for hypoparathyroidism consists of calcium and calcitriol, but sometimes normal serum calcium cannot be maintained, and/or this approach might lead to nephrocalcinosis, nephrolithiasis, or renal insufficiency. OBJECTIVE: The objective of the study was to investigate the effects of 6 months of PTH(1-34) treatment in adult subjects with postoperative hypoparathyroidism and to evaluate quality-of-life changes. DESIGN: This was a 2-year prospective, open-label study. At baseline and after 6 months of PTH(1-34) treatment, calcium and vitamin D supplementation requirements, serum calcium, phosphate, creatinine, alkaline phosphatase, uric acid, and 24-hour urinary calcium excretion were evaluated. Quality of life was evaluated by the Rand 36-Item Short Form Health Survey covering eight domains of physical and mental health. SETTING: This was an Italian multicentric study. PARTICIPANTS: Participants included 42 subjects with surgical hypoparathyroidism (90% females, age range 34-77 y). INTERVENTION: The intervention included a twice-daily PTH(1-34) 20 μg sc injection. RESULTS: The mean serum calcium levels significantly increased from baseline to 15 days (7.6 ± 0.6 vs 9.1 ± 0.9 mg/dL, P < .001) and remained stable until the end of the observational period, despite a significant reduction in calcium and vitamin D supplementation. Phosphate levels gradually decreased from baseline to the sixth month (P = .005 for the trend), whereas the alkaline phosphatase increased (P < .001). Data from the Rand 36-Item Short Form Health Survey showed a significant improvement in the mean scores of all eight domains (P < .001). CONCLUSION: This is the largest study that demonstrates the effectiveness of PTH(1-34) in the treatment of adult patients with postsurgical hypoparathyroidism, and it shows that PTH(1-34) may improve the mental and physical health in hypoparathyroid subjects.
CONTEXT: Conventional therapy for hypoparathyroidism consists of calcium and calcitriol, but sometimes normal serum calcium cannot be maintained, and/or this approach might lead to nephrocalcinosis, nephrolithiasis, or renal insufficiency. OBJECTIVE: The objective of the study was to investigate the effects of 6 months of PTH(1-34) treatment in adult subjects with postoperative hypoparathyroidism and to evaluate quality-of-life changes. DESIGN: This was a 2-year prospective, open-label study. At baseline and after 6 months of PTH(1-34) treatment, calcium and vitamin D supplementation requirements, serum calcium, phosphate, creatinine, alkaline phosphatase, uric acid, and 24-hour urinary calcium excretion were evaluated. Quality of life was evaluated by the Rand 36-Item Short Form Health Survey covering eight domains of physical and mental health. SETTING: This was an Italian multicentric study. PARTICIPANTS: Participants included 42 subjects with surgical hypoparathyroidism (90% females, age range 34-77 y). INTERVENTION: The intervention included a twice-daily PTH(1-34) 20 μg sc injection. RESULTS: The mean serum calcium levels significantly increased from baseline to 15 days (7.6 ± 0.6 vs 9.1 ± 0.9 mg/dL, P < .001) and remained stable until the end of the observational period, despite a significant reduction in calcium and vitamin D supplementation. Phosphate levels gradually decreased from baseline to the sixth month (P = .005 for the trend), whereas the alkaline phosphatase increased (P < .001). Data from the Rand 36-Item Short Form Health Survey showed a significant improvement in the mean scores of all eight domains (P < .001). CONCLUSION: This is the largest study that demonstrates the effectiveness of PTH(1-34) in the treatment of adult patients with postsurgical hypoparathyroidism, and it shows that PTH(1-34) may improve the mental and physical health in hypoparathyroid subjects.
Authors: Venkatesh Krishnan; Yanfei L Ma; Catherine Z Chen; Natasha Thorne; Heather Bullock; Gregory Tawa; Christy Javella-Cauley; Shaoyou Chu; Weiming Li; Wayne Kohn; Mary D Adrian; Charles Benson; Lifei Liu; Masahiko Sato; Wei Zheng; Andre M Pilon; N Nora Yang; Henry U Bryant Journal: Br J Pharmacol Date: 2017-11-28 Impact factor: 8.739
Authors: Kelly L Roszko; Tiffany Y Hu; Lori C Guthrie; Beth A Brillante; Michaele Smith; Michael T Collins; Rachel I Gafni Journal: J Bone Miner Res Date: 2021-10-18 Impact factor: 6.390
Authors: Amanda R Doubleday; Sarah E Robbins; Cameron L Macdonald; Dawn M Elfenbein; Nadine P Connor; Rebecca S Sippel Journal: Surgery Date: 2020-07-09 Impact factor: 3.982
Authors: Sofia Ish-Shalom; Yoseph Caraco; Nariman Saba Khazen; Michal Gershinsky; Auryan Szalat; Phillip Schwartz; Ehud Arbit; Hillel Galitzer; Jonathan Cy Tang; Gregory Burshtein; Ariel Rothner; Arthur Raskin; Miriam Blum; William D Fraser Journal: J Bone Miner Res Date: 2021-03-05 Impact factor: 6.741